Company Overview - Azenta, Inc. is a leading provider of sample management and laboratory solutions for the global life sciences industry, leveraging advanced automation and integrated service offerings to support research, drug development, and biobanking initiatives [6] - The company has a market capitalization of $1.6 billion, with a revenue of $593.8 million and a net income of $23.7 million for the trailing twelve months [4] Recent Developments - Meros Investment Management disclosed a new position in Azenta, acquiring 159,945 shares valued at approximately $4.6 million, representing 2% of the fund's $234.2 million in reportable U.S. equity holdings [2][10] - Azenta's shares are currently priced at $35.05, reflecting a 22% decline over the past year, significantly underperforming the S&P 500, which increased by 13% during the same period [3] Financial Performance - The company reported a 310-basis-point increase in adjusted EBITDA margin, with an additional 300 basis points of margin expansion expected for the next fiscal year, indicating a potential profitability reset [9] - Fourth-quarter organic growth was driven by an 11% surge in Multiomics, and adjusted EBITDA rose 29% year over year, suggesting improving fundamentals [10] Business Model - Azenta generates revenue through sales of life science products and recurring service contracts, including sample storage, genomic sequencing, and laboratory analysis, serving pharmaceutical and biotechnology companies, biorepositories, and research institutes across various regions [8]